An observational study in Coronary Artery Disease, Percutaneous Coronary Intervention and Acute Coronary Syndrome, sponsored by Seoul National University Hospital. Status unknown at 20 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2016-07-27.
Sponsored by Seoul National University Hospital · Observational
The objectives of this study are
Secondary endpoints of this study are
Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI
Target vessl failure
Composite rate of cardiac death and any MI, 3 years
Composite rate of all death and any MI
Composite rate of all death, any MI, and any repeat revascularization
Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's planned enrollment of 1,533 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
All coronary arterial disease patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent(s)
Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form
Exclusion Criteria:
The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
Device: Alpine
Also known as: Everolimus-eluting stent
Target lesion failure
Composite of cardiac death, non-fatal target vessel-related myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)
Time frame: 12 months
Target vessel failure
Composite of cardiac death, non-fatal target vessel related myocardial infarction, and ischemia-driven target vessel revascularization (TVR)
Time frame: 12 months
Composite rate of cardiac death and myocardial infarction
Time frame: 12 months, 3 years
Composite rate of all-cause death and any myocardial infarction
Time frame: 12 months, 3 years
Composite rate of all-cause death and any myocardial infarction, and any repeat revascularization
Time frame: 12 months, 3 years
Rate of compliance and interruptions with prescribed adjunctive antiplatelet therapy
Time frame: 12 months, 3 years
Clinical device and procedural success rate
Time frame: intraoperative
Stent thrombosis
acute (within 24 hours), subacute (1 - 30 days), late (31 days - 1 year), very late (\>1 year)
Time frame: within 24 hours, 1 - 30 days, 31 days - 1 year, after 1 year
This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital